Pharma-Bio Serv (PBSV) Non-Current Debt (2020 - 2021)
Pharma-Bio Serv posted quarterly Non-Current Debt of $643900.0 for Q2 2021, down 50.0% year-on-year from $1.3 million in Q2 2020, and little changed on a QoQ basis from $643900.0 in Q1 2021.
Pharma-Bio Serv (PBSV) has 2 years of Non-Current Debt data on file, last reported at $643900.0 in Q2 2021.
- For the quarter ending Q2 2021, Non-Current Debt fell 50.0% year-over-year to $643900.0; the trailing twelve-month figure through Apr 2021 stood at $643900.0 (down 50.0% YoY), and the FY2020 full-year result was $643900.0, changed N/A from the prior year.
- Non-Current Debt for Q2 2021 stood at $643900.0, roughly flat from $643900.0 in the prior quarter.
- Across five years, Non-Current Debt topped out at $1.3 million in Q2 2020 and bottomed at $643900.0 in Q4 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Veeva Systems | 30.85 Bn | 24.28 Bn | 622.47 Mn | - |
| 2 | BrightSpring Health Services | 12.29 Bn | 11.41 Bn | 482.22 Mn | 2.44 Bn |
| 3 | Healthequity | 7.80 Bn | 7.48 Bn | 256.31 Mn | 942.66 Mn |
| 4 | Hinge Health | 4.82 Bn | 4.51 Bn | 154.23 Mn | - |
| 5 | Doximity | 4.21 Bn | 3.46 Bn | 125.97 Mn | - |
| 6 | Waystar Holding | 4.18 Bn | 4.03 Bn | 268.04 Mn | 1.46 Bn |
| 7 | 10x Genomics | 3.78 Bn | 3.24 Bn | 106.18 Mn | - |
| 8 | Privia Health | 2.65 Bn | 2.28 Bn | 595.71 Mn | - |
| 9 | Omnicell | 1.95 Bn | 1.78 Bn | 140.36 Mn | - |
| 10 | Pharma-Bio Serv | - | - | 722,374.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2021 | 643,900.00 |
| Apr 30, 2021 | 643,900.00 |
| Jan 31, 2021 | 643,900.00 |
| Jan 31, 2021 | 643,900.00 |
| Oct 31, 2020 | 643,900.00 |
| Oct 31, 2020 | 643,900.00 |
| Jul 31, 2020 | 965,850.00 |
| Jul 31, 2020 | 965,850.00 |
| Apr 30, 2020 | 1.29 Mn |
| Apr 30, 2020 | 1.29 Mn |